drugset / Trial / NCT00453063

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)

NCT00453063

Phase 3 Completed 426 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to assess the effectiveness of mometasone furoate nasal spay (MFNS) once daily (QD) compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score and the total ocular symptom score.

Timeline

Start
2007-03
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mometasone furoate Other / unclassified 200 ug Intranasal